Genghis Lloyd-Harris

Bio

Joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) and was a Managing Director in the European Equity Research Group based in London. Was responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to 2003. Before joining Equity Research at CSFB, worked for CSFB's Health Care Group in the Investment Banking Division in New York. Was previously a paediatrician in Melbourne, Australia. Focuses on exits of Abingworth’s venture investments via mergers and acquisitions and IPOs as well as venture investment in the UK and Continental Europe. Current and past directorships have included HBI, Novexel, Solexa and Synosia Therapeutics Holds a Medical Degree from the University of Liverpool in the UK, a PhD in Clinical Pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School.